Howard v. Zimmer, Inc.

711 F.3d 1148, 2012 WL 7800834
CourtCourt of Appeals for the Tenth Circuit
DecidedJuly 3, 2012
DocketNo. 11-5109
StatusPublished
Cited by2 cases

This text of 711 F.3d 1148 (Howard v. Zimmer, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Tenth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Howard v. Zimmer, Inc., 711 F.3d 1148, 2012 WL 7800834 (10th Cir. 2012).

Opinion

CERTIFICATION OF QUESTION OF STATE LAW

CARLOS F. LUCERO, Circuit Judge.

This appeal presents a novel issue of Oklahoma law: Does Oklahoma recognize a claim for negligence per se founded on an alleged violation of a federal regulation promulgated under the Medical Device Amendments (“MDA”) to the Food, Drug, and Cosmetic Act (“FDCA”)? Although this case has involved numerous issues in several federal courts, this state-law question is the only one remaining. Because Oklahoma law is not settled on this point, we respectfully certify the question to the Oklahoma Supreme Court.

I

Dr. Brian Howard was the recipient of a knee implant manufactured by Sulzer Orthopedics, Inc. (“Sulzer”).1- The implant [1150]*1150failed to bond to Howard’s bone and, as a result, it had to be removed. According to Howard, the implant’s failure was due to an oily residue left on the implant as a result of Sulzer’s negligent manufacturing process.

This litigation began in 2002 in the Northern District of Oklahoma, where Dr. Howard and his wife filed suit alleging various claims. Because the Howards’ complaint was one of many asserting the failure of Sulzer implants, the Judicial Panel on Multidistrict Litigation consolidated the cases in the Northern District of Ohio. In a series of rulings, the Ohio district court granted summary judgment to Sulzer on all of the Howards’ claims, holding that each was expressly preempted by the MDA.

Under the MDA, no state may impose requirements on medical devices that are “different from, or in addition to” those imposed by the FDCA. 21 U.S.C. § 360k(a). The Supreme Court has interpreted that section to apply to state tort suits. Riegel v. Medtronic, Inc., 552 U.S. 312, 323-24, 128 S.Ct. 999, 169 L.Ed.2d 892 (2008). Thus, if a plaintiffs theory of liability is premised on a manufacturer’s act or omission that is not required by the statute, the claim is expressly preempted.

The Howards appealed the dismissal of their negligence per se claim to the Sixth Circuit. With respect to that claim, the Howards argued that the applicable standard of care was defined by a “Good Management Practice” (“GMP”) regulation promulgated by the Food and Drug Administration (“FDA”). Specifically, the Howards rest on the following GMP:

Where a manufacturing material could reasonably be expected to have an adverse effect on product quality, the manufacturer shall establish and maintain procedures for the use and removal of such manufacturing material to ensure that it is removed or limited to an amount that does not adversely affect the device’s quality. The removal or reduction of such manufacturing material shall be documented.

21 C.F.R. § 820.70(h). The Howards’ theory is that this regulation required Sulzer to remove all manufacturing oil from the knee implant, and that Sulzer’s failure to do so constituted negligence per se.

Before the Sixth Circuit, Sulzer pressed a series of arguments to support the district court’s judgment.2 It first argued that the GMP did not apply. In the alternative, Sulzer contended that the GMP only required that a process be in place to remove oil, not that Sulzer actually remove all oil on the implant. Relatedly, Sulzer claimed that if the GMP did not require actual removal of oil, a negligence per se claim based on failure to remove the oil would impose a requirement in addition to those stated by the FDCA, and would thus be expressly preempted.

In a separate section of their brief, Sul-zer also argued that the negligence per se claim was impliedly preempted under Buckman Co. v. Plaintiffs’ Legal Committee, 531 U.S. 341, 121 S.Ct. 1012, 148 L.Ed.2d 854 (2001). The Buckman Court considered a claim that a manufacturing consultant fraudulently misled the FDA during the medical device approval process. Noting that the federal statutory scheme reserves exclusive enforcement power for the FDA and explicitly disallows private rights of action, the Court held that a fraud-on-the-FDA claim was impliedly preempted by the FDCA. Id. at 352, [1151]*1151121 S.Ct. 1012 (citing 21 U.S.C. § 337(a)). Drawing on language from Buckman, Sul-zer argued that any claim that relied exclusively on a violation of the FDCA or MDA to establish the breach of a duty of care was impliedly preempted. The How-ards countered that Sulzer’s reading of Buckman was overbroad, suggesting instead that Buckman is limited to fraud-on-the-FDA claims.

Faced with Sulzer’s two separate preemption arguments — express and implied — the Sixth Circuit held that the Howards’ “negligence per se claim for GMP violations is not preempted.” Howard v. Sulzer Orthopedics, Inc., 382 Fed.Appx. 436, 442 (6th Cir.2010) (unpublished). The Sixth Circuit’s preemption analysis, however, focused exclusively on express preemption: The court interpreted the GMP at issue to require actual oil removal and thus concluded that Howards’ claim for negligence per se did not impose any additional requirements beyond the FDCA. Id. at 439-41. The opinion does not cite Buckman, however, nor does it discuss implied preemption. In a petition for rehearing, Sulzer further pressed its Buckman point, arguing that “[t]he [panel's decision conflicts with Buckman ... because it holds that a negligence per se claim based on an allegation that Sulzer failed to comply [with] FDA [Regulations is not preempted.” The Sixth Circuit declined to rehear the case.

On remand from the Sixth Circuit, the Howards’ action was transferred back to the Northern District of Oklahoma. Sul-zer filed a renewed motion for summary judgment, requiring the district court to consider briefing on an issue that the Sixth Circuit had explicitly declined to consider: whether the remaining, non-preempted claim for negligence per se was cognizable under OHahoma state law. Although it acknowledged the precise issue had not been decided by Oklahoma state courts, the district court predicted that such a cause of action would not be recognized and dismissed the Howards’ sole remaining claim. The Howards now appeal that decision.

II

Apart from simply urging affir-mance of the district court’s Oklahoma-law ruling, Sulzer asks us to revive the preemption issue in this case, on the theory that the Sixth Circuit did not decide the question of implied preemption under Buckman. We disagree and accordingly decline Sulzer’s request.

The law of the case doctrine generally requires us to respect any decision of a sibling circuit issued at an earlier stage of the case. See Rohrbaugh v. Celotex Corp., 53 F.3d 1181, 1183 (10th Cir.1995)(an appellate court’s decision should be followed by “both the trial court on remand and the appellate court in any subsequent appeal”). The Sixth Circuit’s omission of any discussion of Buckman

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Spurlock v. Townes
594 F. App'x 463 (Tenth Circuit, 2014)
Howard v. Zimmer, Inc.
718 F.3d 1209 (Tenth Circuit, 2013)

Cite This Page — Counsel Stack

Bluebook (online)
711 F.3d 1148, 2012 WL 7800834, Counsel Stack Legal Research, https://law.counselstack.com/opinion/howard-v-zimmer-inc-ca10-2012.